A BELGIAN REGISTRY OF INTERLEUKIN-2 ADMINISTRATION FOR TREATMENT OF METASTATIC RENAL CELL CANCER AND CONFRONTATION WITH LITERATURE DATA

A BELGIAN REGISTRY OF INTERLEUKIN-2 ADMINISTRATION FOR TREATMENT OF METASTATIC RENAL CELL CANCER AND CONFRONTATION WITH LITERATURE DATA

In an effort to map the use of interleukin-2 (IL-2) treatment in patients with clear cell renal cell cancer (RCC) in Belgian hospitals, 44 cases were registered from 9 hospitals between February 2003 and June 2006. It was demonstrated that the majority of these patients were treated with subcutaneou...

Full description

Saved in:
Bibliographic Details
Published in:Acta clinica belgica (English ed. Online) Vol. 62; no. 4; pp. 223 - 229
Main Authors: Bambust, I., Van Aelst, F., Joosens, E., Schallier, D., Rezaei Kalantari, H., Paulus, R., Renard, V., Clausse, M., Duck, L., Luce, S., Pierre, P., Van Belle, S., Rottey, S.
Format: Journal Article
Language:English
Published: England Taylor & Francis 01-08-2007
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents - administration & dosage
Belgium
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - secondary
cytokines
Drug Utilization - statistics & numerical data
Female
Humans
Interleukin-2 - administration & dosage
Male
metastatic renal cell cancer
Middle Aged
Practice Patterns, Physicians' - statistics & numerical data
Registries
Retrospective Studies
targeted drugs
Treatment Outcome
Belgium
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In an effort to map the use of interleukin-2 (IL-2) treatment in patients with clear cell renal cell cancer (RCC) in Belgian hospitals, 44 cases were registered from 9 hospitals between February 2003 and June 2006. It was demonstrated that the majority of these patients were treated with subcutaneous (SC) IL-2. Other methods such as the inhalation of the drug in case of intrathoracic disease or high dose intravenous (IV) administration were much less frequent (3 and 0 cases in this registry, respectively). The results of antitumour activity (around 16% partial response - absence of complete responses) and toxicity of this drug correlate with observations from the literature with the SC administration. In view of the poor results and tolerance with the currently used cytokines (IL-2 or interferon-alfa), much hope is directed towards the development of the novel targeted drugs like sunitinib or sorafenib used alone or in combination with cytokines in this disease.
ISSN:1784-3286
2295-3337
DOI:10.1179/acb.2007.036